Journal Article Summary
The article investigates the combination of two chemotherapy drugs, mitomycin C (MMC) and irinotecan, to see if they can help overcome tumor resistance in patients with advanced solid tumors. This topic is important because irinotecan is often used to treat various cancers, but many tumors develop resistance to it, making treatment less effective. By exploring the potential of MMC to enhance the effectiveness of irinotecan, the study aims to improve outcomes for patients facing difficult-to-treat cancers.
In this study, 45 patients with advanced solid malignancies participated in a two-part trial. Initially, patients received a fixed dose of MMC along with escalating doses of irinotecan, which was later adjusted due to side effects like diarrhea. The second part of the study introduced celecoxib, but this combination led to severe toxicities, resulting in the conclusion that adding celecoxib did not provide additional benefits. The researchers found that the combination of irinotecan and MMC showed some anti-tumor activity, with 16 patients experiencing varying degrees of tumor response, including one complete response.
However, the study had limitations, including a small sample size and significant side effects, such as myelosuppression and diarrhea, which raised safety concerns. Patients should be aware that while the combination of MMC and irinotecan may be promising, it also carries risks of serious side effects. It is essential for patients and caregivers to discuss these findings and any potential treatment options with their healthcare professionals to make informed decisions about cancer treatment.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Xu Y., Kolesar J. M., Schaaf L. J., Drengler R., Duan W., Otterson G., Shapiro C., Kuhn J., et al.. Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer chemotherapy and pharmacology 2008. DOI: 10.1007/s00280-008-0826-3. PMID: 18795290. PMCID: PMC3933356.
Featured Pill Pals Product
Celecoxib 100 mg Capsules --- Generic For Celebrex --- Mullan
Celecoxib 100 mg Capsules — Generic For Celebrex — Mullan is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
